VIRGINIA RETIREMENT SYSTEMS ET Al Makes New $1.46 Million Investment in Bruker Corporation $BRKR

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Bruker Corporation (NASDAQ:BRKR) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 24,200 shares of the medical research company’s stock, valued at approximately $1,456,000.

Several other institutional investors and hedge funds have also recently modified their holdings of BRKR. Allworth Financial LP raised its position in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares during the last quarter. Federated Hermes Inc. grew its position in Bruker by 6.7% during the 4th quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock valued at $284,000 after purchasing an additional 380 shares during the last quarter. Parallel Advisors LLC increased its stake in Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares in the last quarter. State of Michigan Retirement System increased its stake in Bruker by 1.9% during the 1st quarter. State of Michigan Retirement System now owns 26,693 shares of the medical research company’s stock valued at $964,000 after purchasing an additional 500 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in Bruker in the fourth quarter worth about $26,000. 79.52% of the stock is currently owned by institutional investors.

Bruker Stock Performance

Shares of BRKR stock opened at $53.43 on Friday. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The company has a 50 day moving average price of $58.25 and a 200-day moving average price of $49.25. Bruker Corporation has a 52 week low of $30.09 and a 52 week high of $65.30. The firm has a market capitalization of $8.14 billion, a PE ratio of -76.33, a P/E/G ratio of 1.63 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. During the same quarter in the prior year, the firm earned $0.32 earnings per share. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities research analysts expect that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 21st. Bruker’s dividend payout ratio (DPR) is -28.57%.

Wall Street Analysts Forecast Growth

BRKR has been the topic of several analyst reports. Wolfe Research started coverage on shares of Bruker in a research note on Monday, June 1st. They issued a “peer perform” rating on the stock. Leerink Partners raised their price target on shares of Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. TD Cowen restated a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Guggenheim upped their price objective on Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research note on Monday, August 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Bruker currently has an average rating of “Hold” and a consensus price target of $57.00.

Bruker Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.